http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+28/26560985.html si-local-file:///var/storage/secattach/20260528/26560985.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+28/26560985.html Thu, 28 May 2026 07:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+28/26560985.html si-local-file:///var/storage/secattach/20260528/26560985.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+28/26560985.html Thu, 28 May 2026 07:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tiziana+Life+Sciences+++++For%3A+Mar+18++Filed+by%3A+Shah+Keeren+Rameshchandra/26542636.html si-local-file:///var/storage/secattach/20260522/26542636.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tiziana+Life+Sciences+++++For%3A+Mar+18++Filed+by%3A+Shah+Keeren+Rameshchandra/26542636.html Fri, 22 May 2026 16:55:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tiziana+Life+Sciences+++++For%3A+Mar+18++Filed+by%3A+Shah+Keeren+Rameshchandra/26542636.html si-local-file:///var/storage/secattach/20260522/26542636.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Tiziana+Life+Sciences+++++For%3A+Mar+18++Filed+by%3A+Shah+Keeren+Rameshchandra/26542636.html Fri, 22 May 2026 16:55:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+21/26533179.html si-local-file:///var/storage/secattach/20260521/26533179.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+21/26533179.html Thu, 21 May 2026 11:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+21/26533179.html si-local-file:///var/storage/secattach/20260521/26533179.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+21/26533179.html Thu, 21 May 2026 11:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+19/26517086.html si-local-file:///var/storage/secattach/20260519/26517086.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+19/26517086.html Tue, 19 May 2026 07:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+19/26517086.html si-local-file:///var/storage/secattach/20260519/26517086.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+19/26517086.html Tue, 19 May 2026 07:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/Corporate+News/Tiziana+reports+brain+inflammation+reduction+in+multiple+system+atrophy+trial/26489757.html <p>Tiziana Life Sciences Ltd. (NASDAQ: TLSA) reported initial results from two patients with Multiple System Atrophy (MSA) treated with its intranasal foralumab therapy in a Phase 2 clinical trial.</p><p>PET scan analysis showed reductions in inflammatory activity in brain regions affected by MSA following treatment with the intranasal anti-CD3 monoclonal antibody. The first two patients demonstrated up to approximately 35% reduction in standardized uptake value and approximately 24% reduction in standardized uptake value ratio in affected brain areas.</p><p>The reductions occurred in the basal ganglia and cerebellar white matter regions, which are involved in the neurodegenerative processes of MSA. PET imaging comparisons http://www.streetinsider.com/Corporate+News/Tiziana+reports+brain+inflammation+reduction+in+multiple+system+atrophy+trial/26489757.html Thu, 14 May 2026 07:03:42 -0400 TLSA http://www.streetinsider.com/FDA/Tiziana+reports+brain+inflammation+reduction+in+multiple+system+atrophy+trial/26489757.html <p>Tiziana Life Sciences Ltd. (NASDAQ: TLSA) reported initial results from two patients with Multiple System Atrophy (MSA) treated with its intranasal foralumab therapy in a Phase 2 clinical trial.</p><p>PET scan analysis showed reductions in inflammatory activity in brain regions affected by MSA following treatment with the intranasal anti-CD3 monoclonal antibody. The first two patients demonstrated up to approximately 35% reduction in standardized uptake value and approximately 24% reduction in standardized uptake value ratio in affected brain areas.</p><p>The reductions occurred in the basal ganglia and cerebellar white matter regions, which are involved in the neurodegenerative processes of MSA. PET imaging comparisons http://www.streetinsider.com/FDA/Tiziana+reports+brain+inflammation+reduction+in+multiple+system+atrophy+trial/26489757.html Thu, 14 May 2026 07:03:42 -0400 TLSA http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Press+Releases/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html <p>BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=thrC85Cw4xxeKreqej34X5Yyq1pTFkYNuk452bb_Wulmoz7OKWCPGRoOMyHi1BOfs00nDQe1owh-DYOnLooZpdhVPSIFeFFOt2vO0SnmNyweDvjNOf3DYZDuPCx3AtEY" rel="nofollow" target="_blank">TLSA</a>) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab.</p> <p>Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to http://www.streetinsider.com/Globe+Newswire/Tiziana+Reports+Reduced+Brain+Inflammation+in+Multiple+System+Atrophy+Patients+Treated+with+Intranasal+Foralumab/26489639.html Thu, 14 May 2026 07:00:00 -0400 A.31368885 O.00473094 O.49918125 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+14/26489682.html si-local-file:///var/storage/secattach/20260514/26489682.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+14/26489682.html Thu, 14 May 2026 07:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+14/26489682.html si-local-file:///var/storage/secattach/20260514/26489682.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Tiziana+Life+Sciences+++++For%3A+May+14/26489682.html Thu, 14 May 2026 07:00:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26418672.html si-local-file:///var/storage/secattach/20260501/26418672.html http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26418672.html Fri, 01 May 2026 17:01:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26418672.html si-local-file:///var/storage/secattach/20260501/26418672.html http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26418672.html Fri, 01 May 2026 17:01:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++NT+20-F++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26409836.html si-local-file:///var/storage/secattach/20260430/26409836.html http://www.streetinsider.com/SEC+Filings/Form++NT+20-F++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26409836.html Thu, 30 Apr 2026 17:01:00 -0400 O.00473094 TLSA http://www.streetinsider.com/SEC+Filings/Form++NT+20-F++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26409836.html si-local-file:///var/storage/secattach/20260430/26409836.html http://www.streetinsider.com/SEC+Filings/Form++NT+20-F++++Tiziana+Life+Sciences+++++For%3A+Dec+31/26409836.html Thu, 30 Apr 2026 17:01:00 -0400 O.00473094 TLSA http://www.streetinsider.com/Corporate+News/Tiziana+Life+Sciences+publishes+preclinical+data+on+long+COVID+treatment/26320939.html <p>Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced the publication of preclinical study results showing its intranasal anti-CD3 antibody treatment reduced neuroinflammation and improved cognitive function in a mouse model of long COVID.</p><p>The study, published as a bioRxiv preprint and conducted by researchers including Akiko Iwasaki from Yale University and Howard L. Weiner from Brigham and Women's Hospital, used a respiratory-restricted SARS-CoV-2 mouse model. The treatment increased regulatory T cells in the brain, reprogrammed microglia, reduced gliosis in white matter and hippocampus, normalized CCL11 levels, and restored neurogenesis.</p><p>The research demonstrated that nasal administration of the anti-CD3 monoclonal antibody was effective both http://www.streetinsider.com/Corporate+News/Tiziana+Life+Sciences+publishes+preclinical+data+on+long+COVID+treatment/26320939.html Thu, 16 Apr 2026 07:00:37 -0400 TLSA